Introduction
============

Hepatocellular carcinoma (HCC) is the third most prevalent cause of cancer-associated mortality worldwide, and is one of the most lethal malignancies ([@b1-ol-0-0-4580]). Currently, HCC is refractory to conventional chemotherapies. Early-stage HCC with normal liver function may be effectively treated with liver resection, transplantation or percutaneously, with patients experiencing a considerable 5-year survival rate. However, the majority of patients are diagnosed at later or inoperable stages ([@b2-ol-0-0-4580]). Generally, the progression of HCC is characterized by numerous aberrant cell behaviors, including the loss of tissue-specific gene expression, a decrease in cell differentiation, an increase in proliferation and the induction of metastasis ([@b3-ol-0-0-4580]). Patients with HCC frequently present with tumor cell invasion and migration prior to a definite diagnosis ([@b4-ol-0-0-4580],[@b5-ol-0-0-4580]). Therefore, it is imperative to clarify the molecular mechanisms underlying HCC etiology, and develop novel therapeutic agents to successfully treat the disease.

With the development of deep gene sequencing technology, an increasing amount of research is being focused on non-coding RNAs (ncRNAs). ncRNAs are transcribed from the human genome, and include microRNAs (miRNAs), small interfering RNAs (siRNAs), long ncRNAs (lncRNAs) and PIWI-interacting RNAs ([@b6-ol-0-0-4580],[@b7-ol-0-0-4580]). A large number of studies have concentrated on siRNAs and miRNAs, with their functions and molecular mechanisms being elucidated in recent years ([@b8-ol-0-0-4580]--[@b10-ol-0-0-4580]). However, the understanding of the functions of lncRNAs in various diseases remains extremely limited. Recent studies have reported that lncRNAs may also serve a key role in transcription, chromatin modification and post-transcriptional processing ([@b11-ol-0-0-4580]--[@b13-ol-0-0-4580]).

The number of studies investigating lncRNAs has increased unexpectedly in recent years ([@b14-ol-0-0-4580],[@b15-ol-0-0-4580]). The nuclear-enriched abundant transcript 2, MALAT1, located at human chromosome 11q13, was reported to exhibit high expression in numerous species, and was demonstrated to regulate primary transcripts either transcriptionally or post-transcriptionally ([@b16-ol-0-0-4580],[@b17-ol-0-0-4580]). Lai *et al* ([@b18-ol-0-0-4580]) reported that MALAT1 expression was upregulated in HCC tissues and cell lines and functioned as an independent prognostic factor for HCC recurrence. HOX transcript antisense RNA (HOTAIR) was noted as an additional lncRNA involved in cancer migration and metastasis. Ishibashi *et al* ([@b19-ol-0-0-4580]) reported that a high expression level of HOTAIR was detected in patients with primary HCC. Patients with high HOTAIR expression consistently exhibit poor prognoses and a low 5-year survival rate. Another extensively investigated lncRNA is maternally expressed 3 (MEG3), which serves an important role in regulating growth and cell development. Braconi *et al* ([@b20-ol-0-0-4580]) reported that MEG3 was downregulated in HCC tumor tissues. Restoration of MEG3 in HCC cells significantly inhibited cell growth and induced apoptosis.

Deep gene sequencing technology has aided the investigation of various dysregulated lncRNAs in HCC. However, when compared with miRNAs, the current understanding of lncRNAs is limited. Previous studies have demonstrated that colon cancer associated transcript 2 (CCAT2) was upregulated in lung and gastric cancer ([@b21-ol-0-0-4580],[@b22-ol-0-0-4580]), indicating that the lncRNA possesses oncogenic characteristics. The present study aimed to verify the expression level of CCAT2 in HCC tissues and cell lines, and assess the impact of CCAT2 on cell proliferation, migration and apoptosis, with the results demonstrating that CCAT2 functions as a oncogene in HCC.

Materials and methods
=====================

### Patients and tissue samples

A total of 50 HCC tissue samples were obtained from 50 different patients between July 2008 and June 2013 from The Second Xiangya Hospital of Central South University (Changsha, China). None of the patients received percutaneous ablation, chemoembolization or radiotherapy prior to surgery. For all patients, paired tumor and non-tumor liver tissue samples were collected immediately following liver resection and were snapfrozen at −80°C until use. The pathological diagnosis was confirmed in all cases by the Department of Pathology, The Second Xiangya Hospital of Central South University. The clinical pathological data of the patients is presented in [Table I](#tI-ol-0-0-4580){ref-type="table"}. The Ethics Committee of The Second Xiangya Hospital of Central South University granted approval for the study prior to sample collection, and the patients or a family member signed a consent form permitting the collection and use of their samples for the present study.

### Cell culture and transfection

HCC cell lines (HepG2, HEP3B, HCCLM3 and HuH7) and one normal liver cell line (L02) were obtained from the American Type Culture Collection (Mannasas, VA, USA). The cells were cultured with Dulbecco\'s modified Eagle\'s medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.). All cells were maintained at 37°C in a humidified chamber with 95% air and 5% CO~2~.

CCAT2 small hairpin RNA (shRNA;target sequence, 5′-UUAACCUCUUCCUAUCUCATT-3′) were purchased from GeneChem Co., Ltd. (Shanghai, China). The CCAT2 overexpression plasmid, CCAT2-pcDNA3.1(+), was synthesized by Life Technologies (Thermo Fisher Scientific, Inc.). HepG2 and HuH7 cells were transfected with 2 µg of CCAT2 shRNA or CCAT2-pcDNA3.1(+) vector using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The ﬁrst-strand cDNA was synthesized using oligo-dT primers from the RevertAid™ First Strand cDNA Synthesis kit (catalog no., K1621; Thermo Fisher Scientific, Inc.). The primers used were as follows: Human CCAT2, forward, 5′-CCCTGGTCAAATTGCTTAACCT-3′, and reverse, 5′-TTATTCGTCCCTCTGTTTTATGGAT-3′; and human glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forward, 5′-CCACATCGCTCAGACACCAT-3′, and reverse 5′-ACCAGGCGCCCAATACG-3′. GAPDH was utilized as an internal control. RT-qPCR was performed using the SYBR^®^ Premix Ex Taq™ II (Tli RNaseH Plus) (catalog no., RR820A; Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer\'s protocol on the Light-cycler 480^®^ II Real-Time PCR System (Roche Diagnostics, Basel, Switzerland). The results were normalized using the 2^−ΔΔCq^ method ([@b23-ol-0-0-4580]). The conditions for PCR were as follows: 98°C for 5 min, followed by 45 cycles of 98°C for 10 sec, 60°C for 30 sec and 72°C for 30 sec. The experiments were performed in triplicate and repeated at least three times.

### Cell proliferation assay

Cell growth was analyzed using an MTT assay performed according to the manufacturer\'s protocol. HepG2 and HuH7 cells (\~1×10^4^ cells) were seeded into a 96-well culture plate 24 h prior to transfection with CCAT2 shRNA and shRNA negative control, or CCAT2-pcDNA3.1(+) vector and pcDNA3.1(+) empty vector. After 0, 24, 48 or 72 h transfection, 20 µl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg/ml; Invitrogen; Thermo Fisher Scientific, Inc.) was added to each plate and incubated for 4 h at 37°C. Subsequently, 150 µl dimethyl sulfoxide was added to each plate and agitated for 10 min at 37°C in order to solubilize the crystals. The number of cells per plate were measured by the absorbance (540 nm) at the indicated time points. Assays were repeated at least three times.

### Cell migration assay

The 24-well Boyden chamber with 8-µm pore size polycarbonate membrane (Corning Incorporated, Corning, NY, USA) was used to evaluate cell motility. HepG2 and HuH7 cells were transfected with CCAT2 shRNA and negative control, or CCAT2-pcDNA3.1(+) vector and pcDNA3.1(+) empty vector using Lipofectamine 2000. Matrigel (BD Biosciences, San Jose, CA, USA) was used to simulate a matrix barrier for the migration assay. Following 48 h of transfection, a total of 4×10^3^ cells were seeded in the upper chamber with 200-µl serum-free medium. A total of 600 µl of medium containing 20% serum, which served as a chemoattractant, was added into the lower chamber. Following 24 h of incubation, the membranes were fixed with methanol and stained with 0.1% crystal violet at 37°C. Three visual fields were randomly selected from each membrane, and the number of cells were counted using a light-microscope. Experiments were run in three independent repeats in triplicate, and were examined in a double-blind manner by at least two observers.

### Cell apoptosis assay

At 48 h post-transfection, apoptosis induced by CCAT2 shRNA and negative control, or CCAT2-pcDNA3.1(+) vector and pcDNA3.1(+) empty vector, was evaluated by calculating the activity of caspase 3 using the Human Caspase 3 ELISA kit (Cusabio, Wuhan, China) and Hoechst 33258 staining (Invitrogen; Thermo Fisher Scientific, Inc.). The results were observed by a Laser Scanning Confocal Microscope (Zeiss AG, Oberkochen, Germany) and analyzed using Image-Pro^®^ Plus 5.1 software (Media Cybernetics Inc, Bethesda, MD, USA). All experiments were performed three times.

### Statistical analysis

Statistical analysis was conducted using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Statistical signiﬁcance was determined with Student\'s t-test. Data are presented as the mean ± standard deviation. For the comparison of CCAT2 expression levels in matched tumor vs. normal samples, a paired t-test was used. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### CCAT2 is upregulated in HCC tissues and cell lines

The endogenous expression of CCAT2 in human HCC tissues was compared with adjacent non-cancerous tissues by RT-qPCR. It was observed that the expression of CCAT2 was significantly upregulated in the HCC tissues when compared with the matched normal liver tissue (P\<0.05; [Fig. 1A](#f1-ol-0-0-4580){ref-type="fig"}). Furthermore, it was demonstrated that CCAT2 expression was significantly higher in all 4 HCC cell lines when compared with that in the normal liver epithelial L02 cells (P\<0.05; [Fig. 1B](#f1-ol-0-0-4580){ref-type="fig"}). Collectively, these results suggest that CCAT2 is upregulated in HCC tissues and cell lines.

### CCAT2 promotes proliferation of HCC cells

To investigate the potential role of CCAT2 in HCC, the inhibitory effect of CCAT2 on HCC cells was analyzed. HepG2 and HuH7 cell proliferation was measured by MTT assay following transfection with CCAT2 shRNA and negative control, or CCAT2-pcDNA3.1(+) vector and pcDNA3.1(+) empty vector. As expected, transfection of the CCAT2-pcDNA3.1(+) vector into the HepG2 and HuH7 cells resulted in a significant increase in CCAT2 expression when compared with the pcDNA3.1(+) empty vector ([Fig. 2A](#f2-ol-0-0-4580){ref-type="fig"}), and the transfection of the CCAT2 shRNA into the HepG2 and HuH7 cells resulted in a decrease in CCAT2 expression when compared with negative control ([Fig. 2B](#f2-ol-0-0-4580){ref-type="fig"}). Furthermore, it was observed that the suppression of CCAT2 expression significantly inhibited the proliferation of the HCC cells, while an increase in its expression promoted cell proliferation ([Fig. 3](#f3-ol-0-0-4580){ref-type="fig"}). These results suggest that CCAT2 may function as an oncogene in the development of HCC.

### CCAT2 promotes HCC cell migration

In order to identify the potential role of CCAT2 in HCC metastasis, the present study investigated the effect of CCAT2 on the migratory capacity of HCC cells. HepG2 and HuH7 cells were transfected with CCAT2 shRNA and negative control or CCAT2-pcDNA3.1(+) vector and pcDNA3.1(+) empty vector, and were then evaluated by cell migration assays. The results demonstrated that the suppression of CCAT2 expression significantly reduced the migration rate of the HepG2 and HuH7 cells when compared with the control ([Fig. 4A](#f4-ol-0-0-4580){ref-type="fig"}). By contrast, the overexpression of CCAT2 significantly increased the migration rate of the HepG2 and HuH7 cells when compared with the control ([Fig. 4B](#f4-ol-0-0-4580){ref-type="fig"}). These results indicate that CCAT2 functions as a oncogenic lncRNA and promotes the migration of HCC cells.

### CCAT2 inhibits HCC cell apoptosis

It has been previously reported that lncRNAs serve a crucial role in cell apoptosis, particularly in the avoidance of apoptosis observed in cancer cells. To determine the impact of CCAT2 on HCC cell apoptosis, an enzyme-linked immunosorbent assay was utilized to measure the rate of apoptosis in the HCC cell lines. As presented in [Fig. 5](#f5-ol-0-0-4580){ref-type="fig"}, the apoptosis rates of the HepG2 cells transfected with CCAT2 shRNA and the CCAT2-pcDNA3.1(+) vector were 28.5 vs. 2.3%, respectively, and the apoptosis rates of the HuH7 cells were 26.1 vs. 16.5%, respectively; thus, demonstrating the upregulation of CCAT2-inhibited HCC cell apoptosis. When combined, the results provide strong evidence of CCAT2 functioning as a oncogene in HCC development.

Discussion
==========

An increasing number of studies have demonstrated that the dysregulation of certain lncRNAs may contribute to tumorigenesis ([@b24-ol-0-0-4580],[@b25-ol-0-0-4580]). lncRNAs form a large family of highly-conserved molecules that regulate a wide array of cancer-associated genes, and may therefore be considered as a novel family of tumor suppressor genes and oncogenes ([@b24-ol-0-0-4580],[@b25-ol-0-0-4580]). The lncRNA CCAT2 is located on chromosome 8q24.21, and is differentially expressed in benign and malignant tumors ([@b26-ol-0-0-4580]--[@b28-ol-0-0-4580]). Previous studies have reported that CCAT2 is overexpressed in gastric and lung cancer ([@b21-ol-0-0-4580],[@b22-ol-0-0-4580]); however, to the best of our knowledge, the expression pattern and functional role of CCAT2 in HCC has not yet been elucidated.

HCC is the fifth most prevalent malignancy and accounts for 85--90% of all primary liver cancer cases ([@b29-ol-0-0-4580]). A number of studies have reported that lncRNAs serve an important function in the regulation of gene expression in cancer development ([@b30-ol-0-0-4580]--[@b32-ol-0-0-4580]). The dysregulation of lncRNAs has been identified in various types of cancer, including HOTAIR in ovarian and colorectal cancer, GAS5 in breast cancer and MALAT1 in prostate cancer ([@b33-ol-0-0-4580]--[@b35-ol-0-0-4580]). The dysregulation of lncRNAs has also been notably indicated in HCC, with H19, hepatocellular carcinoma up-regulated EZH2-associated lncRNA, microvascular invasion in HCC, hepatocellular carcinoma up-regulated lncRNA and MEG3 demonstrating dysregulation in HCC ([@b36-ol-0-0-4580]--[@b38-ol-0-0-4580]). Therefore, determination of the expression profile and function of aberrant lncRNAs in HCC would be particularly useful to further understand how lncRNAs assist the development of the disease.

In the present study, the expression of CCAT2 was analyzed in 50 HCC tissues samples, with the results demonstrating that CCAT2 expression is higher in HCC tissues compared with paired adjacent non-tumoral tissues. Recent studies have reported that CCAT2 was upregulated in numerous types of cancer, which suggests that CCAT2 may function as a oncogene in cancer ([@b22-ol-0-0-4580],[@b39-ol-0-0-4580]). Previous studies have also demonstrated that CCAT2, a regulator of malignant cell progression, was associated with metastatic processes in human cancer. To elucidate the role of CCAT2 in the development of HCC, the present study performed HCC cell transfection. Restoration of CCAT2 in the HCC cells, as a result of transfection with the synthetic overexpression CCAT2-pcDNA3.1(+) vector, was demonstrated to promote proliferation and migration. In addition, the downregulation of CCAT2 in the HCC cells inhibited the proliferation and migration of the HCC cells. The results of the present study suggest that CCAT2 serves a crucial role in HCC cell proliferation, migration and apoptosis.

In conclusion, the current study demonstrated that CCAT2 was upregulated in HCC tissue, and indicated that this lncRNA may function in HCC development through the dysregulation of cellular migration, proliferation and apoptosis. CCAT2 is a promising biomarker and/or a therapeutic target for HCC, with further study required to elucidate the underlying molecular mechanisms of CCAT2 in HCC development.

![CCAT2 was upregulated in the HCC tissues and cell lines. (A) RT-qPCR analyzed CCAT2 expression relative to GAPDH expression in 50 HCC tissue samples (Cancer) compared with matched non-cancerous liver tissue (Normal). (B) RT-qPCR analyzed CCAT2 expression levels in the HCC HepG2, HEP3B, HCCLM3 and HuH7 cell lines compared with the normal liver L02 cell line. Data are expressed as the mean ± standard deviation (n=3). \*P\<0.05. CCAT2, colon cancer associated transcript 2; HCC, hepatocellular carcinoma; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.](ol-12-01-0132-g00){#f1-ol-0-0-4580}

![Transfection of CCAT2 shRNA and negative control or CCAT2-pcDNA3.1(+) vector and pcDNA3.1(+) empty vector to HepG2 and HuH7 cells alters the expression of CCAT2. (A) Transfection of the CCAT2-pcDNA3.1(+) vector to the HepG2 and HuH7 cells increases the expression of CCAT2 when compared with pcDNA3.1(+) empty vector. (B) Transfection of CCAT2 shRNA to the HepG2 and HuH7 cells decreases the expression of CCAT2 when compared with the negative control. Values are expressed as the mean ± standard deviation. The experiments were performed in duplicate and repeated three times. \*P\<0.05. CCAT2, colon cancer associated transcript 2; shRNA, small hairpin RNA.](ol-12-01-0132-g01){#f2-ol-0-0-4580}

![CCAT2 promotes the proliferation of HCC cells. MTT assay demonstrated significant inhibition of cell proliferation in CCAT2 shRNA transfected (A) HepG2 and (B) HuH7 cells when compared with the control. MTT assay demonstrated significant promotion of cell proliferation in CCAT2-pcDNA3.1(+) vector transfected (C) HepG2 and (D) HuH7 cells when compared with the empty vector. All experiments were performed three times and a representative picture is presented. \*P\<0.05. OD, optical density; CCAT2, colon cancer associated transcript 2; HCC, hepatocellular carcinoma; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; shRNA, small hairpin RNA.](ol-12-01-0132-g02){#f3-ol-0-0-4580}

![CCAT2 promotes HCC cell migration. (A) HepG2 and HuH7 cells transfected with CCAT2 shRNA or negative control. The suppression of CCAT2 expression significantly reduced the migration rate of the HCC cell lines when compared to the control. (B) HepG2 and HuH7 cells transfected with CCAT2-pcDNA3.1(+) vector or pcDNA3.1(+) empty vector. Overexpression of CCAT2 signifcantly increased the migration rate of the HCC cell lines when compared to the control. Values are expressed as the mean ± standard deviation. Each experiment was repeated three times. \*P\<0.05.](ol-12-01-0132-g03){#f4-ol-0-0-4580}

![CCAT2 inhibits HCC cell apoptosis. (A) Apoptosis rates of HepG2 and HuH7 cells were increased after transfection with CCAT2 shRNA compared with the negative control. (B) Apoptosis rates of HepG2 and HuH7 cells were decreased after transfection with CCAT2-pcDNA3.1(+) vector compared with the pcDNA3.1(+) empty vector. Nuclei were counterstained with Hoechst 33258. Comparison of HepG2 and HuH7 cell apoptosis rates following transfection with (C) CCAT2 shRNA and the negative control or (D) the CCAT2-pcDNA3.1(+) vector and the pcDNA3.1(+) empty vector. Values are expressed as the mean ± standard deviation. \*P\<0.05. CCAT2, colon cancer associated transcript 2; shRNA, small hairpin RNA.](ol-12-01-0132-g04){#f5-ol-0-0-4580}

###### 

Clinical and pathological characteristics of patients with hepatocellular carcinoma.

  Characteristics      Number of patients
  -------------------- --------------------
  Age, years           
    ≤50                22
    \>50               28
  Gender               
    Male               37
    Female             13
  Tumor size, cm       
    ≤5                 27
    \>5                23
  Clinical TNM stage   
    I                    7
    II                 28
    III                13
    IV                   2

TNM, tumor-node-metastasis.
